Osteoprotegerin
Osteoprotegerin (OPG) belongs to the tumor necrosis factor receptor (TNFR) superfamily. Osteoprotegerin blocks the RANKL-RANK interaction as well as the binding of TRAIL to its receptor. Osteoprotegerin activates NF-κB to induce the expression of ICAM-1, VCAM-1 and E-selectin, and activates the phosphorylation of ERK1/2. Osteoprotegerin regulates osteoclast activity, inhibits osteoclast maturation and formation, bone lysis and bone resorption, and increases bone mass. Osteoprotegerin regulates vascular endothelial cell function. Osteoprotegerin can be used in the research of cardio-cerebrovascular and bone-related diseases.
For research use only. We do not sell to patients.
- CAS No.: 19220-35-0
- Formula: C18H32O2
- Molecular Weight:280.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Osteoprotegerin (OPG/TRAIL ratio 1:1-6:1) dose-dependently inhibits TRAIL-induced migration activity of mesenchymal stem cells in vitro; complete inhibition is observed at an OPG/TRAIL ratio of 6:1, while no inhibition is detected at a ratio of 1:1[1].
Osteoprotegerin inhibits RANKL-induced matrix metalloproteinase activity in human vascular smooth muscle cells *in vitro* by sequestering RANKL and preventing its binding to RANK[1].
Osteoprotegerin induces the expression of ICAM-1, VCAM-1 and E-selectin by activating NF-κB, mediates direct cell surface signaling pathways via its heparin-binding domain, and enhances leukocyte adhesion to human vascular endothelial cells in vitro[1].
Osteoprotegerin dose-dependently upregulates the expression of AT1 receptors in human vascular smooth muscle cells and cells derived from atherosclerotic plaques, and directly activates the phosphorylation of ERK1/2 in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 19220-35-0
-
Molecular Weight 280.45
-
Formula C18H32O2
-
SMILES
O=C(CCCCCC#CCCCCCCCCCC)O
-
Synonyms
OPG
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Dutka M, et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. Heart failure reviews. 2022 Jul;27(4):1395-1411. [Content Brief]
[2]. Payr S, et al. Direct comparison of 3D and 2D cultivation reveals higher osteogenic capacity of elderly osteoblasts in 3D. Journal of orthopaedic surgery and research. 2021 Jan 06;16(1):13. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)